<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563352</url>
  </required_header>
  <id_info>
    <org_study_id>0S-17-4</org_study_id>
    <secondary_id>NCI-2018-00948</secondary_id>
    <secondary_id>0S-17-4</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT03563352</nct_id>
  </id_info>
  <brief_title>Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer</brief_title>
  <official_title>Evaluating Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements for Oncologic Patients - A Cross-Sectional Survey Study at Norris Comprehensive Cancer Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies nutritional preferences and product accessibility in oral nutritional&#xD;
      supplements in participants with breast, colorectal, upper gastrointestinal, or prostate&#xD;
      cancer. Learning what participants like and dislike about their current or past used&#xD;
      nutritional supplements may help doctor know how to improve them.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Identify how patients with cancer are obtaining nutrition to support medical management.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Examine associations of gastrointestinal side effects with specific diagnoses and&#xD;
      respective medical therapies.&#xD;
&#xD;
      II. Understand how patients access information regarding nutritional supplements.&#xD;
&#xD;
      III. Evaluate patient satisfaction with currently available oral nutritional supplements&#xD;
      (ONS).&#xD;
&#xD;
      IV. Identify patient preferences in formulating a novel nutritional supplement.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants attend an interview over 15 minutes and complete surveys.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Zero accrual&#xD;
  </why_stopped>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Actual">September 24, 2020</completion_date>
  <primary_completion_date type="Actual">September 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The way patients with cancer choose and obtain nutritional supplements to support medical management</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Data from the oral nutritional supplement survey that examines quality, quantity, access and affordability of oral nutrional supplements will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associations of gastrointestinal side effects with specific diagnoses and respective medical therapies</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Data from the survey will be used for testing the association of gastrointestinal side effects with specific diagnosis and medical therapies.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Gastric Carcinoma</condition>
  <condition>Malignant Digestive System Neoplasm</condition>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Observational (interview, survey)</arm_group_label>
    <description>Participants attend an interview over 15 minutes and complete surveys.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>Attend an interview</description>
    <arm_group_label>Observational (interview, survey)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (interview, survey)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the diagnosis of breast cancer, colorectal cancer, upper gastrointestinal&#xD;
        cancer (including gastric, pancreatic, and cholangiocarcinoma), and prostate cancer who are&#xD;
        seen at the USC facilities will be screened and recruited for this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to comprehend English (both reading and writing)&#xD;
&#xD;
          -  Subjects in the inpatient and outpatient setting with the diagnosis of breast cancer,&#xD;
             colorectal cancer, upper gastrointestinal cancer (including gastric, pancreatic, and&#xD;
             cholangiocarcinoma), or prostate cancer&#xD;
&#xD;
          -  Receiving chemotherapy, biologic, or hormonal therapy in the University of Southern&#xD;
             California (USC) Norris Comprehensive Cancer Center Day Hospital&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a mental disability that makes them unable to understand and respond to&#xD;
             the questions&#xD;
&#xD;
          -  Patients with reported non-oncologic associated deficits in taste and smell&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Pinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

